Advanced age is a strong predictor of high perioperative mortality in surgical patients and patients aged 75 years and older have an elevated surgical risk, much higher than that of younger patients. Progressive advances in surgical techniques now make it possible to treat high-risk surgical patients with minimally invasive procedures. Endovascular techniques have revolutionized the treatment of several vascular diseases, in particular carotid stenosis, aortic pathologies, and severely incapacitating intermittent claudication or critical limb ischemia. The main advantages of the endovascular approach are the low complication rate, high rate of technical success and a good clinical outcome. Biliary stenting has improved the clinical status of severely ill patients with bile duct stricture before major surgery, and represents a good palliative therapy in the case of malignant biliary obstruction.
Introduction
Advanced age is a strong predictor of high perioperative mortality, and patients over 75 years of age have a far higher surgical risk than younger patients. Progressive advances in surgical techniques now make it possible to treat high-risk surgical patients with minimally invasive procedures. Endovascular techniques have revolutionized the treatment of several vascular diseases, in particular carotid stenosis, aortic pathologies, and severely incapacitating intermittent claudication or critical limb ischemia. The main advantages of the endovascular approach are the low complication rate, high rate of technical success and a good clinical outcome even in the long term. Biliary stenting has improved the clinical status of severely ill patients with bile duct stricture before major surgery, and represents a good palliative therapy in the case of malignant biliary obstruction.
Percutaneous treatment of peripheral artery occlusive disease
Percutaneous transluminal angioplasty (PTA) is a mini-invasive technique for the treatment of patients affected by severely incapacitating intermittent claudication or critical limb ischemia [1] . The main advantages of the endovascular approach are the low rate of complications, which range from 0.5 to 4%, the high rate of technical success, estimated around 90% also for the treatment of long occlusions, and the good clinical outcome [2] . Currently, PTA is the therapy of choice for revascularization of the aortoiliac and femoropopliteal arteries and arteries of the leg: in fact in many centers, endovascular therapy is the therapeutic approach most frequently adopted [3] . However, it is not without complications, particularly the rate of incidence of restenosis is still unacceptably high. The main obstacle to the placement of first-generation nitinol metal stents is the marked intimal hyperplasia which is responsible for intrastent restenosis in 25% of cases at 12 months and in 50% at 24 months. In the course of recent years, drug-eluting balloons (DEBs) have been created, as well as new types of stent both metallic and medicated (drug-eluting stent, DES), covered stent grafts, and new systems of atherectomy to reduce the incidence of restenosis and improve the long term outcomes. The second-generation nitinol stents have a greater flexibility, particularly in the axial sense, and more resistance to fracture, characteristics which make these stents indicated also for the treatment of more complex lesions; the SUPERA SFA registry enrolled 107 patients with complex femoropopliteal lesions treated with insertion of a Supera stent, showing a patency rate of 76% at 24 months [4] . Today, PTA with a DEB, hence without stent placement, is becoming more and more common. The technique with DEB as opposed to PTA with stent placement allows a homogeneous release of the antiproliferative drug to the vessel wall without the need to leave foreign prosthetic material in situ which could trigger an inflammatory process, and a potentially shorter duration of the dual antiplatelet therapy. In addition, the DEB can be applied in Original Article
Aortic dissection
Acute type A aortic dissection, i.e. with involvement of the ascending aorta -following Stanford's classification, is an urgent surgical intervention with an extremely high mortality rate, estimated between 28 and 58% of patients who are operated rapidly [13] . Advanced age is a strong predictor of high perioperative mortality: in fact, in 2001, the rate of perioperative mortality in patients in their 80s was reported to be 83% [14] ; however, in the last few years, thanks to technological advances and greater experience of surgeons in handling this disease, the rate has dropped to 13-25%, accompanied though by an increase in the number of patients surviving who present severely invalidating post-treatment outcomes. The IRAD study has demonstrated that, despite the significant increase in the rate of surgical mortality with advancing age, surgical treatment of patients aged <80 years is associated to significantly lower rates of in-hospital mortality than medical therapy, and surgery can reduce the in-hospital mortality also in patients in their 80s affected by type A aortic dissection; thus, surgical treatment could be considered in all patients with type A aortic dissection independently of their age. For patients with dissection of the thoracic aorta without involvement of the ascending aorta (Stanford type B dissection), endovascular treatment through insertion of an endoprosthesis, as an alternative to open surgery, is an extremely interesting therapeutic innovation due to its reduced invasiveness, enabling the treatment also of patients at high surgical risk, and thus representing a life-saving therapeutic option that can prevent complications such as aortic rupture and malperfusion syndrome [13] . The endoprosthesis functions through a skeleton of nitinol which exerts a radial force and has properties of elasticity, thermal memory and extreme robustness. Hemodynamically stable patients are usually treated conservatively with medical therapy (survival rate at 1 year ≥80%), but the long-term results are disappointing due to the possible expansion of the aneurysm and a cumulative mortality of 30% at 5 years. The therapeutic rationale for insertion of an endoprosthesis is to promote thrombosis of the false lumen provoking the occlusion and, thus, reestablish the normal anatomy of the aorta. With respect to open surgery, a lower incidence of mortality and morbidity is reported, particularly for complications related to medullary ischemia.
Biliary stenting
Biliary stenting is a procedure consisting of the insertion of a tubular prosthesis to eliminate a constriction of the biliary duct wall and prevent their reformation. The indications for this procedure are biliary duct obstruction caused by neoplasms of the pancreas, gallbladder, biliary ducts, liver or colon, damage to the biliary ducts arising following removal of the gallbladder or following a pancreatitis, primitive sclerosing colangitis, gallstones, radiotherapy, or abdominal injuries. The procedure can thus be performed to improve patients' clinical status before major surgery or as definitive palliative therapy in the case of malignant biliary obstruction. The prosthesis can be positioned with the aid of endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) [15] . In the first case, before inserting the stent, a sphincterectomy is performed which allows direct access to the interior of the biliary ducts; in some cases, however, before inserting the stent the obstructed biliary duct is expanded by inflating a balloon in its interior. PTC, on the other hand, involves needle puncture of the biliary ducts through the skin at the level of the right hip or epigastric region, to provide access anatomical zones which are sites of movement, such as the common femoral artery and popliteal artery, in which the placement of a stent could be subject to frequent complications due to fracture of the stent itself [5, 6] . Nevertheless, there are limitations to the use of DEB, such as the incapacity to treat flaps of dissecations, and a lower efficacy in the case of severely calcified arteries on account of the smaller quantity of antiproliferative drug absorbed by the arterial wall.
Stenting of the carotid artery
Ischemic stroke is caused in 10-15% of all cases by a stenosis of the internal carotid artery. In patients with carotid artery disease, the aim of revascularization is to prevent stroke. For about 50 years, carotid endoarterectomy (CEA) was the standard treatment for severe carotid stenosis. But, over the last 15 years, carotid artery stenting (CAS) has gained acceptance as an alternative to open surgery -this mini-invasive treatment was developed as a method of carotid revascularization in situations where CEA was technically difficult to perform or in patients at high surgical risk [7] . The comorbidities associated to a high risk of complications with endoarterectomy include: elderly age (> 75 years), chronic heart failure in NYHA class III or IV, unstable angina (CCS III/IV), chronic ischemic heart disease involving epicardial vessels with >70% stenosis, recent acute myocardial infarction (AMI), severe aortic stenosis, ejection fraction <30%, severe COPD, and severe chronic kidney failure. Elderly patients thus constitute a patient group that can benefit from endovascular treatment [8, 9] . In the CREST trial, in which 2502 patients were enrolled, one group underwent carotid stenting with the cerebral protection system and another group underwent CEA. During a mean follow-up of 2.5 years, no significant difference was observed in the incidence of primary endpoints (stroke, AMI, death for any cause during the periprocedural phase, ipsilateral stroke within 4 years after randomization into the study) between patients who underwent stenting and those who underwent CEA (7.2 and 6.8%, respectively; HR 1.11; 95% CI 0.81-1.51; p=0.51) [10] . Nevertheless, of note there was, in the second half of the study, a significant reduction in the rate of stroke in the group of patients who underwent stenting, suggesting a learning curve effect on the endovascular technique. A meta-analysis involving 3754 patients treated with stenting and 3723 patients who underwent CEA showed that, at 30 days from revascularization, the endovascular technique was significantly associated to a high risk of stroke and of mortality, while the incidence of AMI and of cranial nerve lesions was significantly higher in the group of patients who underwent open surgery, especially symptomatic patients and elderly patients; in addition, 30 days from revascularization, the efficacy of the two strategies in terms of prevention of homolateral ictus and their safety in terms of restenosis or need to repeat the revascularization was similar in all studies [11] . Recently, a double layer mesh stent has been developed with greater flexibility enabling it to adapt to an eventual tortuous path of the carotid artery while, at the same time, it consents an optimal cover of the plaque. The double layer mesh stent is characterized by an internal layer of mesh micromesh to cover the plaque and a self-expandable external layer in nitinol which guarantees the characteristic flexibility of the open-cell stents [12] . The size of the micromesh cell is extremely small (0.381 mm 2 ) permitting an accurate cover of the plaque, rendering this technology safe and promising: in fact, at 30 days from revascularization this stent is associated with a low percentage of plaque prolapse and an optimal clinical outcome, but it remains to be seen if it will reduce the neurological events associated with the endovascular procedure at long-term follow-up. Original Article to the duct for successive positioning of the stent in the biliary site. This treatment reestablishes normal patency of the biliary duct in 90% of cases. However, the procedure is not without complications, such as occlusion or dislocation of the stent, infections, cholecystitis, hemorrhage, pancreatitis, cholangitis, and intestinal lesions in the case of ERCP.
Discussion
Advances in surgical techniques have made it possible to treat patients at high surgical risk with increasingly less-invasive procedures. Endovascular surgery has revolutionized the therapeutic approach to many steno-obstructive vascular diseases due to its advantages of a low rate of complications, elevated percentage of technical success and good clinical outcomes also in the long term. However, the endovascular approach is still today limited by a high rate of restenosis, the main underlying pathophysiological cause of which is myointimal hyperplasia, triggered by inflammatory-immunological processes. For decades, carotid endoarterectomy represented the standard treatment for severe carotid stenosis; today, stenting of the carotid artery is considered a mini-invasive alternative to open surgery, which enables revascularization even in cases where endoarterectomy is technically difficult or in patients at high surgical risk. Thoracic aortic dissection is a dramatic event, aggravated by an extremely high rate of mortality. For patients with thoracic aortic dissection without involvement of the ascending aorta (Stanford type B aortic dissection) the insertion of an endoprosthesis, as an alternative to open surgery, constitutes a therapeutic technique with reduced invasiveness that permits the treatment also of patients at high surgical risk, with the aim to close the intimal tear, interrupt the blood flow in the false lumen and promote thrombosis of the latter. Also, the treatments of endoscopic surgery of the biliary ways and biliary stenting have improved the clinical status of patients with occlusions or stricture of the biliary ducts, representing a non-obstructive treatment alternative to open surgery in the case of biliary stones, or a temporary or definitive palliative treatment in the case of malignant biliary obstruction.
Conclusions
Advanced age is a predictor of high perioperative mortality in surgical patients. Advances in surgical techniques have made it possible to treat patients at high surgical risk through procedures which are increasingly less invasive. In particular, endoscopic surgery of the biliary ducts and endovascular treatments have revolutionized in recent years the therapeutic approach to many steno-obstructive biliary and vascular diseases; nevertheless, they are marked by a consistent rate of complications and relapse, which represents the current challenge for clinical research. 
